Median Technologies SA develops and markets software solutions and services for the use of medical images for the diagnosis and monitoring of patients with cancer in Europe, North America, and Asia. The company offers iC…
Industry Peers
Medical Devices| Headline | Source | Time |
|---|---|---|
Older | ||
 Median Technologies and Olea sign partnership for lung cancer device The eyonis LCS Software as a Medical Device uses AI to help clinicians detect and diagnose lung cancer earlier. | ||
 Median Technologies and Olea sign partnership for lung cancer device The eyonis LCS Software as a Medical Device uses AI to help clinicians detect and diagnose lung cancer earlier. | ||
 Tempus AI Reinforces Market Position With Collaborations in 2026 TEM expands 2026 reach via strategic collaborations, boosting oncology, diagnostics and AI-driven insights to enhance care and drug development. | ||
 H.C. Wainwright Raises Tempus AI (TEM) Price Target to $95 Tempus AI, Inc. (NASDAQ:TEM) is among the 10 Best New AI Stocks to Buy. On March 9, H.C. Wainwright analyst Yi Chen raised the firm’s price target on Tempus AI, Inc. (NASDAQ:TEM) to $95 from $89 while maintaining a Buy rating. The analyst highlighted the company’s expanding network of strategic partnerships, including collaborations with Merck & Co., […] | IInsider Monkey | |
 Why Tempus AI (TEM) Is Down 7.5% After 2025 Results, 2026 Outlook And ESOP Shelf Registration - And What's Next Tempus AI recently reported full-year 2025 results, with revenue rising to US$1.27 billion and net loss narrowing to US$245.03 million, alongside 83% year-over-year Q4 growth driven by diagnostics. At the same time, Tempus AI issued 2026 guidance, launched its HRD-RNA oncology algorithm, expanded lung cancer screening distribution through Median Technologies, and filed a US$343.38 million ESOP-related shelf registration, underscoring an effort to scale its AI-enabled precision medicine... | ||
Tempus AI Deepens Precision Oncology Role With New HRD And Lung Tools Tempus AI (NasdaqGS:TEM) has launched a new AI-driven HRD-RNA algorithm aimed at improving cancer diagnostics. The company has entered a partnership with Median Technologies to bring advanced lung cancer screening solutions onto its platform. The collaboration follows recent FDA clearance of Median’s eyonis LCS tool for lung cancer screening. For investors watching the growth of AI in healthcare, Tempus AI sits at the intersection of data, diagnostics, and oncology. The new HRD-RNA... | ||
Tempus AI Expands Cancer Workflow With HRD-RNA Launch And Lung Screening Tempus AI launched its HRD-RNA algorithm, an AI-driven model for identifying Homologous Recombination Deficiency in cancer patients. The company also partnered with Median Technologies to integrate the eyonis LCS AI tool for lung cancer screening in the US and Europe. These updates expand Tempus AI's diagnostic offerings in both treatment selection and early lung cancer detection. Tempus AI, trading on NasdaqGS:TEM, is drawing attention with these product and partnership moves at a share... | ||
 Here's How Tempus AI Is Tapping the Imagining Space TEM expands into radiology via Median partnership, adding AI lung screening to Pixel as FDA clearance and past deals boost imaging push. | ||
 Tempus AI & Median Partner to Add AI Lung Cancer Screening to Pixel TEM teams with Median to add FDA-cleared eyonis LCS to Pixel, boosting AI lung cancer screening and expanding its imaging portfolio. | ||
 Median Technologies establishes distribution partnership with Tempus AI Median Technologies’ eyonis (LCS) software, which recently gained FDA clearance, will be integrated into Tempus AI’s cardiac imaging platform. | ||
 FDA clears Median Technologies’ lung nodule evaluation software Median's eyonis LCS is software is reimbursable under Medicare at a rate between $601 to $700. | ||